Viatris And Mapi Knocked Back On Once-Monthly US Copaxone Rival
CRL For GA Depot 40mg Means Approval Denied; Are Manufacturing Issues At Play?
Executive Summary
Viatris offered little in the way of detail as it announced a setback for its Mapi Pharma-partnered proposed once-monthly glatiramer acetate product for relapsing forms of multiple sclerosis. The firm has previously shouted from the rooftops about Mapi’s Phase III clinical study and the potential to establish a new standard of care for glatiramer acetate patients.